- ASSISTANT PROFESSOR Genetics and Genomic Sciences
- ASSISTANT PROFESSOR Emergency Medicine
American Board of Emergency Medicine
MD, New Jersey Medical School - Rutgers University
Internship, Internal Medicine
University Hospital (UMDNJ)
Residency, Emergency Medicine
Long Island Jewish Medical Center
Dr. Yvonne Chan is a board-certified Emergency Medicine physician with a PhD in clinical research as well as experience in mobile health applications, pharmacogenomics, clinical trials and patient education.
During Dr. Chan’s 7 years at New Jersey Medical School, she served as the Associate then Research Director for the EM residency and medical student EM electives as well as the fieldwork site supervisor for the MD/MPH students. Dr. Chan was the principal investigator for the Stroke Education Center in the Emergency Department Waiting Room studies and was also a co-investigator for a CDC HIV Counseling, Testing, and Referral Services project.
In 2008, Dr. Chan took an EM faculty position at Icahn School of Medicine at Mount Sinai to pursue formal research training. After a two year NIH/National Institute of Neurological Disorders and Stroke (NINDS) T32 Post-doctoral Cerebrovascular Research Fellowship at Sinai, she was awarded the NIH Institutional KL2 Clinical and Translational Research Career Development Award and received her PhD in Clinical Research from the Mount Sinai Graduate School of Biological Sciences. Dr. Chan’s dissertation was on the Pharmacogenetics of clopidogrel in the Mount Sinai Biobank Cohort. During her training, she was the co-investigator of three NINDS clinical trials: the ‘Platelet-Oriented Inhibition in New TIA and minor ischemic stroke (POINT), Tenecteplase (TNK) in acute ischemic stroke, and the Discharge Education Strategies for Reduction of Vascular Events (DESERVE) trials. In addition, she collaborated with the Institute of Personalized Medicine faculty on the CLIPMERGE (CLinical Implementation of Personalized Medicine through Electronic Health Records and Genomics) project. Currently, she is a co-investigator on the Patients with Mild Stroke: Rapidly Improving Symptoms and Neurologic Deficits (PRISMS) Trial.
In 2014, Dr. Chan joined the Institute of Genomics and Multiscale Biology as the Director of Personalized Medicine (PM) and Digital Health (DH). Her role is to lead the Institute in clinical trial study design, execution, and management of all DH and PM related clinical trials and initiatives conducted at the institute. She also serves as the collaborator and client liaison for these projects.
· Mobile Health Applications
· Personalized Medicine
· Clinical Trials
· Stroke genomics
· Patient education
Nationally, Dr. Chan was elected as Chair of the Society of Academic Emergency Medicine's Neurological Interest Group. She was an American College of Emergency Medicine representative for the NINDS Brain Attack Coalition Stroke Messaging Committee and a participant at the NIH Roundtable on Opportunities to advance Research on Neurological and Mental Health Emergencies. She is a member of the American Stroke Association Stroke Committees as well as the International Stroke Genetics Consortium (ISGC). In addition, she is a writing group member of the American Heart Association Guidelines for CPR and Emergency Cardiovascular Care as well as the ISGC Protocols and Guidelines.
Within the Mount Sinai system, Dr. Chan chaired the Stroke Arrivals Committee and serves as the Emergency Medicine liaison for the Comprehensive Stroke Center as well as the Stroke Emergency Medicine Combined Conference.
Northern New Jersey Annual Volunteer Recognition Power to End Stroke Honoree
American Heart Association/ American Stroke Association
Semi-Finalist for UMDNJ Process Improvement and Innovation Award
Stroke/Transient Ischemic Attack Disease Process Team
Best Resident Researcher
Department of Emergency Medicine
Dr. Chan's current research interests include Cerebrovascular and Cardiovascular genomics, Pharmacogenomics, Stroke clinical trials.
Chan YF, Sproule W, Ordonez E, Nagurka R. Medical Utilization of Kiosks.. Health Promotion Perspectives;.
Moskowitz A, Chan YF, Singhal A. Chemistry and Biochemistry of Oxygen Therapeutics: From Transfusion to Artificial Blood.. In: Normobaric and Hyperbaric Oxygen Therapy for Ischemic Stroke and Other Conditions.. John Wiley & Sons, Ltd.; 2011.prettyprintppp. 159-177.
Chan YF, Jauch EC, Cucchiara B, Adeoye O, Meurer W, Brice J. Part 11: adult stroke. 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care 2010 Nov; 2(122): 818-28.
Chan YF, D'Onofrio G, Jauch E, Jagoda A. NIH Roundtable on Opportunities to Advance Research on Neurologic and Psychiatric Emergencies. Jauch E, Jagoda A, Allen MH, Anglin D, Barsan WG, Berger RP, Bobrow BJ, Boudreaux ED, Bushnell C, Chan YF, Currier G, Eggly S, Ichord R, Larkin GL, Laskowitz D, Neumar RW, Newman-Toker DE, Quinn J, Shear K, Todd KH, Zatzick D; Roundtable External Participants and Roundtable Steering Committee and Federal Participants. . Ann Emergency Medicine 2010 Nov; 56(6): 551-64.
Chan YF, Alagappan K, Rella J, Bentley S, Soto-Greene M, Martin M. Interpreter services in the Emergency Department.. Journal of Emergency Medicine 2010 Feb; 38(2): 133-139.
Chan YF, Richardson L, Zaets S, Nagurka R. The Effectiveness of Stroke Education in the Emergency Department Waiting Room. . Journal of Stroke and Cerebrovascular Diseases. 2010; 19(3): 209-215.
Chan YF, Moskowitz A, Bruns J. Barriers to Telestroke Implementation: A Pilot Survey of Physician Attitudes and Beliefs. Stroke 2010; 41(4): 805-9.
Chan Y, Levine S, Silbergleit R, Jagoda A. Viewpoint: SAEM Retires Policy Statement on Lytic Therapy in Stroke. 2010;.
Chan Y, Katz M, Moskowitz A, Levine S, Richardson L, Tuhrim S, Chason K, Barsan K, Singhal A. Supplemental Oxygen Delivery to Suspected Stroke Patients in Pre Hospital and Emergency Department Settings . Medical Gas Research;.
Majersik J. Recommendations from the International Stroke Genetics Consortium, Part 1: Standardized Phenotypic Data Collection. Stroke;.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr. Chan did not report having any of the following types of financial relationships with industry during 2014 and/or 2015: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website at http://icahn.mssm.edu/about-us/services-and-resources/faculty-resources/handbooks-and-policies/faculty-handbook. Patients may wish to ask their physician about the activities they perform for companies.
One Gustave L. Levy Place
New York, NY 10029